Literature DB >> 2115446

Absorption kinetics of oral and rectal flecainide in healthy subjects.

L Lie-A-Huen1, J H Proost, J H Kingma, D K Meijer.   

Abstract

UNLABELLED: The absorption kinetics of different pharmaceutical formulations of orally and rectally administered flecainide have been assessed in a cross-over study in 7 healthy volunteers. The subjects received single doses of flecainide after a washout period of at least one week. A tablet, an oral solution, a rectal solution and a 10 min i.v. infusion during 10 min each containing 100 mg flecainide were administered to the subjects in a randomized order. The mean absolute bioavailability was 98%, 78% and 81% for the rectal and oral solutions and the tablet. The lag time after administration of the oral solution was 0.33 h and it was 0.86 h after the tablet and 0.18 h after the rectal solution. The mean time to the peak serum concentration (tmax) after the rectal solution (0.67 h) was shorter than after either the tablet (4 h) or oral solution (1 h). The maximum serum concentration (Cmax) was 0.29 mg.l-1 after the rectal solution, 0.14 mg.l-1 after the tablet and 0.17 mg.l-1 after the oral solution. All the volunteers showed significantly higher serum flecainide concentrations during the first 20 min of the absorption phase after rectal administration of 100 mg flecainide as a solution compared to its oral administration. IN
CONCLUSION: based on the absolute bioavailability, Cmax, tmax, and lag times, rectal administration of flecainide solution gave a better absorption profile than after oral tablet or solution.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2115446     DOI: 10.1007/bf00278588

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  High-performance liquid chromatographic assay of flecainide and its enantiomers in serum.

Authors:  L Lie-A-Huen; R M Stuurman; F N Ijdenberg; J H Kingma; D K Meijer
Journal:  Ther Drug Monit       Date:  1989-11       Impact factor: 3.681

2.  Clinical usefulness of flecainide acetate in the treatment of paroxysmal supraventricular arrhythmias.

Authors:  A J Camm; K J Hellestrand; A W Nathan; R S Bexton
Journal:  Drugs       Date:  1985       Impact factor: 9.546

Review 3.  Metabolism of flecainide.

Authors:  G J Conard; R E Ober
Journal:  Am J Cardiol       Date:  1984-02-27       Impact factor: 2.778

4.  Episodic drug treatment in the management of paroxysmal arrhythmias.

Authors:  B Margolis; R A DeSilva; B Lown
Journal:  Am J Cardiol       Date:  1980-03       Impact factor: 2.778

5.  Rectal absorption of flecainide acetate.

Authors:  L Lie-A-Huen; J H Kingma
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm.

Authors:  M J Suttorp; J H Kingma; L Lie-A-Huen; E G Mast
Journal:  Am J Cardiol       Date:  1989-03-15       Impact factor: 2.778

Review 7.  Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  B Holmes; R C Heel
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546

  7 in total
  3 in total

1.  Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia.

Authors:  Kosuke Doki; Masato Homma; Keisuke Kuga; Kazutomi Kusano; Shigeyuki Watanabe; Iwao Yamaguchi; Yukinao Kohda
Journal:  Eur J Clin Pharmacol       Date:  2006-08-30       Impact factor: 2.953

2.  Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation.

Authors:  V H M Deneer; L Lie-A-Huen; J H Kingma; J H Proost; S A Gossen; A Stuurman; G M M Uytdehaag; P H J M Dunselman; J R B J Brouwers
Journal:  Eur J Clin Pharmacol       Date:  2004-11-16       Impact factor: 2.953

3.  Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation.

Authors:  N J Alp; J A Bell; M Shahi
Journal:  Heart       Date:  2000-07       Impact factor: 5.994

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.